An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Rheumatoid Arthritis
Both
Rheumatoid Arthritis
Trial Information
An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies
Inclusion Criteria:
- Signed informed consent
- Diagnosis of rheumatoid arthritis
- > 18 years at index treatment initiation or switch
- Starting treatment with abatacept or new disease-modifying anti-rheumatic drug
(including switching or adding) or biologic disease modifying drug.
- Read/write English
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Key safety outcomes (targeted infections, malignancies, mortality)
Outcome Time Frame:
Every 6 months throughout the study
Safety Issue:
Yes
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Institutional Review Board
Study ID:
IM101-045B
NCT ID:
NCT01088360
Start Date:
October 2006
Completion Date:
January 2015
Related Keywords:
- Rheumatoid Arthritis
- Arthritis
- Arthritis, Rheumatoid
Name | Location |
|---|
